These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 31206593

  • 1. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ.
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [Abstract] [Full Text] [Related]

  • 2. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.
    Edwards CJ, Monnet J, Ullmann M, Vlachos P, Chyrok V, Ghori V.
    Clin Rheumatol; 2019 Dec; 38(12):3381-3390. PubMed ID: 31396834
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
    Cai L, Li L, Cheng H, Ding Y, Biao Z, Zhang S, Geng S, Liu Q, Fang H, Song Z, Lu Y, Li S, Guo Q, Tao J, He L, Gu J, Yang Q, Han X, Gao X, Deng D, Li S, Wang Q, Zhu J, Zhang J.
    Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
    [Abstract] [Full Text] [Related]

  • 4. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A, Lacour JP, Fowler JF, Weinberg JM, Gospodinov D, Schuck E, Jauch-Lembach J, Balfour A, Leonardi CL.
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.
    Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D.
    Am J Clin Dermatol; 2022 Sep; 23(5):719-728. PubMed ID: 35934770
    [Abstract] [Full Text] [Related]

  • 7. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B.
    Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
    [Abstract] [Full Text] [Related]

  • 8. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
    Menter A, Arenberger P, Balser S, Beissert S, Cauthen A, Czeloth N, Soung J, Jazayeri S, Weisenseel P, Jayadeva G.
    Expert Opin Biol Ther; 2021 Jan; 21(1):87-96. PubMed ID: 33317345
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
    Feldman SR, Reznichenko N, Pulka G, Kingo K, George Galdava, Berti F, Sobierska J, Dias R, Guenzi E, Hendrik Otto, Haliduola HN, Kay R, Stroissnig H.
    BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274
    [Abstract] [Full Text] [Related]

  • 10. A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
    Yu C, Zhang F, Ding Y, Li Y, Zhao Y, Gu J, Guo S, Pan W, Jin H, Sun Q, Kang X, Yang Q, Jiang X, Song Z, Lu Q, Pang X, Kuang Y, Deng D, Li Y, Zhang C, Tao J, Xie L, Wang Y, Wang J, Wang G.
    Int Immunopharmacol; 2022 Nov; 112():109248. PubMed ID: 36126411
    [Abstract] [Full Text] [Related]

  • 11. Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
    Feldman SR, Kay R, Reznichenko N, Sobierska J, Dias R, Otto H, Haliduola HN, Sattar A, Ruffieux R, Stroissnig H, Berti F.
    BioDrugs; 2023 Jul; 37(4):551-567. PubMed ID: 37204631
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
    Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R.
    Arthritis Res Ther; 2021 Sep 25; 23(1):248. PubMed ID: 34563243
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM, Thaçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J, EGALITY study group, Hattebuhr N, Poetzl J, Woehling H, Wuerth G, Afonso M.
    Br J Dermatol; 2017 Apr 25; 176(4):928-938. PubMed ID: 27787890
    [Abstract] [Full Text] [Related]

  • 16. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
    Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, Assudani D.
    Ann Rheum Dis; 2018 Jun 25; 77(6):914-921. PubMed ID: 29514803
    [Abstract] [Full Text] [Related]

  • 17. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
    Jaworski J, Matucci-Cerinic M, Schulze-Koops H, Buch MH, Kucharz EJ, Allanore Y, Kavanaugh A, Young P, Babic G.
    Arthritis Res Ther; 2019 May 28; 21(1):130. PubMed ID: 31138316
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.